In Vitro Assessment of Re-treatment Options for Patients with Hepatitis C Virus Genotype 1b Infection Resistant to Daclatasvir Plus Asunaprevir

Jacques Friborg; Nannan Zhou; Zhou Han; Xiaoyan Yang; Paul Falk; Patricia Mendez; Fiona McPhee

首页> 外文期刊>Infectious Diseases and Therapy >In Vitro Assessment of Re-treatment Options for Patients with Hepatitis C Virus Genotype 1b Infection Resistant to Daclatasvir Plus Asunaprevir

【24h】

In Vitro Assessment of Re-treatment Options for Patients with Hepatitis C Virus Genotype 1b Infection Resistant to Daclatasvir Plus Asunaprevir

机译：达拉他韦加Asunaprevir耐药的丙型肝炎病毒基因型1b感染患者的再治疗选择的体外评估

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Introduction Daclatasvir is a non-structural protein 5A (NS5A) inhibitor with activity against hepatitis C virus (HCV) genotypes 1–6 in vitro, and asunaprevir is a non-structural protein 3 (NS3) protease inhibitor with activity against genotypes 1, 4, 5, and 6. This study evaluates potential options for the re-treatment of HCV genotype 1b-infected patients who have failed combination therapy with daclatasvir plus asunaprevir.

机译：简介Daclatasvir是一种非结构蛋白5A（NS5A）抑制剂，在体外对1-6型肝炎病毒（HCV）基因具有活性，而asunaprevir是一种非结构蛋白3（NS3）蛋白酶抑制剂，对基因型1，4具有活性。，5和6。这项研究评估了重新治疗达卡他韦加Asunaprevir联合治疗失败的HCV基因型1b感染的患者的潜在选择。

著录项

来源
《Infectious Diseases and Therapy》 |2015年第1期|共8页
作者
Jacques Friborg; Nannan Zhou; Zhou Han; Xiaoyan Yang; Paul Falk; Patricia Mendez; Fiona McPhee;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类传染病;
关键词

相似文献

外文文献
中文文献
专利

1. Daclatasvir and asunaprevir treatment in patients infected by genotype 1b of hepatitis C virus with no or subtle resistant associated substitutions (RAS) in NS5A-Y93 [J] . Ishigami Masatoshi, Hayashi Kazuhiko, Honda Takashi, Journal of Medical Virology . 2018,第4期

机译：Daclatasvir和Asunaprevir治疗在乙型肝炎病毒的基因型1b感染患者中，NS5A-Y93中没有或微妙的抗性相关取代（RAS）
2. Efficacy and Safety of Daclatasvir and Asunaprevir in Patients with Hepatitis C Virus Genotype 1b Infection on Hemodialysis [J] . Byung Seok Lee, Myeong Jun Song, Jung Hyun Kwon, Gut and Liver . 2019,第2期

机译：达卡他韦和阿舒那普韦在丙型肝炎病毒基因1b型血液透析患者中的疗效和安全性
3. Daclatasvir Plus Asunaprevir for the Treatment of Patients with Hepatitis C Virus Genotype 1b Infection: Real-World Efficacy, Changes in Liver Stiffness and Fibrosis Markers, and Safety [J] . Hye Won Lee, Se Rim Oh, Dong Yun Kim, Gut and Liver . 2018,第3期

机译：达克他韦加Asunaprevir用于治疗丙型肝炎病毒基因型1b感染的患者：实际疗效，肝硬度和纤维化标志物变化以及安全性
4. Influence of hepatitis C virus genotypes and F protein on outcome of HCV infection among injection drug users [C] . Yun Zhang, Jingjing Yang, Haopeng Wang, International symposium on pharmacogenomics and the regulation of drug metabolism enzymes and genes. . 2010

机译：丙型肝炎病毒基因型和F蛋白对注射吸毒者HCV感染结局的影响
5. Preclinical development of a prophylactic genotype 1a/1b consensus hepatitis C virus DNA vaccine. [D] . Latimer, Brian Paul. 2014

机译：预防性基因型1a / 1b共识性丙型肝炎病毒DNA疫苗的临床前开发。
6. In Vitro Assessment of Re-treatment Options for Patients with Hepatitis C Virus Genotype 1b Infection Resistant to Daclatasvir Plus Asunaprevir [O] . Jacques Friborg, Nannan Zhou, Zhou Han, 2015

机译：对达卡他韦加Asunaprevir耐药的丙型肝炎病毒基因型1b感染患者的再治疗选择的体外评估
7. In Vitro Assessment of Re-treatment Options for Patients with Hepatitis C Virus Genotype 1b Infection Resistant to Daclatasvir Plus Asunaprevir [O] . 2015

机译：达拉他韦加Asunaprevir耐药的丙型肝炎病毒基因型1b感染患者的再治疗选择的体外评估

In Vitro Assessment of Re-treatment Options for Patients with Hepatitis C Virus Genotype 1b Infection Resistant to Daclatasvir Plus Asunaprevir

摘要

著录项

相似文献

相关主题

期刊订阅